Kestra Medical Technologies Ltd. (KMTS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Kestra Medical Technologies Ltd. (NASDAQ: KMTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $29.69 (-3.01% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KMTS ranks #292 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KMTS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 51.4%, and ROIC of -35.0%. By comparison, ATEC (Alphatec Holdings Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
Per KMTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001877184), Kestra Medical Technologies Ltd. generated $95.1M in revenue (+59.0% YoY), -$131.6M in net income, and -$116.6M in free cash flow against $379.3M in total assets and $42.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.4% realized swing band)
Altman Z-Score 9.65 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While KMTS currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.76) and Max Pain ($31.17) forces dealer call-delta covering toward $33.77.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Kestra Medical Technologies Ltd. (KMTS) dropped -3.01% to $29.69, trading at 90% of its 52-week range ($17.34 – $31.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming
Evercore ISI Group analyst Vijay Kumar initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Outperform rating and announces Price Target of $34.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KMTS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KMTS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Kestra Medical Technologies Ltd. (KMTS) ranks #292 by composite RQD confidence (50/100, grade D) and #278 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with KMTS at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KMTS
ACTIVE
Kestra Medical Technologies Ltd. | D | 50/100 | — | 51.4% | -35.0% | -3.01% | $1.82B | Benchmark Subject |
| ATEC Alphatec Holdings Inc. | D | 46/100 | — | 69.6% | -18.4% | -38.08% | $1.76B | /atec-vs-kmts → |
| XRAY DENTSPLY SIRONA Inc. | E | 32/100 | — | 50.0% | -11.0% | -0.83% | $1.92B | /xray-vs-kmts → |
| LMAT LeMaitre Vascular Inc. | C+ | 69/100 | 33.8x | 71.5% | 14.7% | -5.08% | $1.95B | /lmat-vs-kmts → |
| INSP Inspire Medical Systems Inc. | C+ | 66/100 | 14.2x | 85.4% | 6.0% | -4.33% | $2.06B | /insp-vs-kmts → |
In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kestra Medical Technologies Ltd. (KMTS) reported GAAP revenue of $95.1M (+59.0% vs. FY2024 revenue of $59.8M , and +242.0% cumulative change since FY2023) , GAAP net income of -$131.6M, operating cash flow of -$81.7M, and free cash flow of -$116.6M (-16.0% YoY). On the balance sheet, KMTS closed FY2025 with $379.3M in total assets against $42.3M in total debt (Altman Z-Score: 9.65, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $95.1M | -$131.6M | -$81.7M | -$116.6M | $379.3M | $42.3M |
| FY2024 (FY) | 2025-04-30 | $59.8M | -$113.8M | -$77.6M | -$100.5M | — | — |
| FY2023 (FY) | 2024-04-30 | $27.8M | -$94.1M | -$72.2M | -$72.2M | — | — |
As of 2026-11-02, Kestra Medical Technologies Ltd. (NASDAQ: KMTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $29.69 (-3.01% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KMTS ranks #292 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KMTS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 51.4%, and ROIC of -35.0%. By comparison, ATEC (Alphatec Holdings Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
Per KMTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001877184), Kestra Medical Technologies Ltd. generated $95.1M in revenue (+59.0% YoY), -$131.6M in net income, and -$116.6M in free cash flow against $379.3M in total assets and $42.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KMTS last traded at $29.69 (-3.01% on volume of 324,940 shares), positioning the stock +10.95% above its 50-day simple moving average ($26.76) and +24.49% above its 200-day simple moving average ($23.85). Across its 52-week range of $17.34 to $31.06, KMTS sits at the 90.0% percentile with a 14-day RSI of 60.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.4% ($26.01 to $33.37).
Why KMTS Stock dropped -3.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, KMTS scores 50 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -6.4%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 14/20 (Altman Z 9.65; Piotroski F 5/9; Debt/Equity 0.15).
The weakest pillars are the cash engine and insider conviction, which together point to the central tradeoff: the company is consuming cash rather than generating it, and insider-flow signals are unsupportive. The strongest pillar is institutional positioning, which indicates that large holders have been net accumulating or positioning through options, even though insider activity is weak. The balance sheet scores moderately well on the forensic measures, with a high Altman Z and low Debt/Equity, which suggests near-term solvency is not the primary concern. The main upside driver a prospective investor would weigh is the possibility that revenue growth converts into cash generation; the main valuation tradeoff is that the stock trades at a $1.82B market cap while reported operating and net margins are deeply negative and FCF yield is negative. Investors evaluating the stock today would need to judge whether the institutional flow signal outweighs the weak fundamental and insider readings.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $95.1M | $-134.7M | $-131.6M | N/A | $-116.6M | $291.3M | $42.3M |
| FY 2024 | $59.8M | $-106.4M | $-113.8M | N/A | $-100.5M | $54.4M | N/A |
| FY 2023 | $27.8M | $-85.1M | $-94.1M | N/A | $-72.2M | N/A | N/A |
Per the SEC financials, revenue rose from $27.8M in FY 2023 to $95.1M in FY 2025, while operating and net losses widened over the same span. The source data reports a gross margin of 51.4%, an operating margin of -60%, and a net margin of -60%, with ROIC at -35%. The Altman Z-Score is 9.65 and the Piotroski F-Score is 5 out of 9, per the Roarable RQD rating. Balance sheet posture shows cash of $291.3M against debt of $42.3M and a Debt/Equity ratio of 0.15 in the forensic pillar data.
Per the recent news wire, the most prominent item is a report that an insider sold shares worth $443,389 according to a recent SEC filing, which appears across several outlets. Other items include a report of three Kestra presentations scheduled for November and December with live webcasts and replays, a Simply Wall St valuation-focus piece questioning whether the stock is fully valued, and a MarketBeat report noting a 9.8% share price climb. All news items are tagged with a YELLOW light and MARKET WIRE impact label. Risk watch items include the insider sale disclosure and the valuation debate. No proprietary signals are present in the Butterfly graph.
Real-time company headlines, analyst actions, and sector developments for Kestra Medical Technologies Ltd. (KMTS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kestra Medical Technologies Ltd. (KMTS) market action, institutional positioning, and fundamental catalysts.
Welcome to the KMTS (Kestra Medical Technologies Ltd.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on KMTS, but look at what you are paying: current EV/EBITDA multiples with 51.4% gross margins. Unless Kestra Medical Technologies Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on KMTS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $30.61 (52-wk range $17.34 - $31.06), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).